MedPath

Fufang Congrong Yizhi Capsules (FCYC) of Cognitive Impairment After Intracerebral Hemorrhage

Phase 4
Recruiting
Conditions
Cognitive Impairment
Intracerebral Hemorrhage
Interventions
Drug: conventional treatment
Drug: FCYC+Conventional treatment
Registration Number
NCT06673602
Lead Sponsor
Qinhuangdao Hospital of Traditional Chinese Medicine
Brief Summary

This is a randomized, controlled clinical study conducted across multiple centers. The neurosurgical robot can be used to treat patients with acute intracerebral hemorrhage (ICH). Establish a cohort comprising 200 participants with cognitive impairment after robot-assisted neurosurgery treatment for ICH. Two hundred participants are randomly assigned to either an experimental group (n=100) or a control group (n=100). The experimental group receive conventional treatment and oral administration of Fufang Congrong Yizhi Capsules (FCYC) for 12 weeks, while the control group receive only conventional treatment. The object of the current study is 1) to observe the security and effectiveness of FCYC and 2) to decipher the contributing factors to cognitive impairment after robot-assisted neurosurgery treatment for intracerebral hemorrhage.

Detailed Description

The mortality and disability rate for intracerebral hemorrhage (ICH) is high, which places a severe burden on both families and society. Robot-assisted neurosurgery is a significant advancement in the development of minimally invasive surgery for ICH. Compared to conventional surgery, the advantages of robotic surgery include precise positioning, a shorter operative time, and greater stability. Cognitive impairment is a common comorbidity in patients with ICH, which significantly affects their daily life. The effectiveness of Fufang Congrong Yizhi Capsules (FCYC) in treating vascular dementia (VaD) and vascular cognitive impairment (VCI) is well established and has been documented in guidelines and expert consensus. So the primary objective of this clinical study is to observe the safety and efficacy of Fufang Congrong Yizhi Capsules (FCYC) of cognitive impairment after robot-assisted neurosurgery treatment for intracerebral hemorrhage

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
200
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Conventional treatment groupconventional treatmentConventional treatment: blood pressure control and care as according to the current guidelines
FCYC groupFCYC+Conventional treatmentConventional treatment combined with oral administration of FCYC (four capsules, three times a day, orally) for a 12-week course of treatment
Primary Outcome Measures
NameTimeMethod
Change in cognitive functioning measured by Montreal Cognitive Assessment (MoCA)at baseline, 3 months, 6 months, 12 months

It is a widely used screening assessment for detecting cognitive impairment. Low score is worse outcome.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (6)

Second Affiliated Hospital of Tsinghua University

🇨🇳

Beijing, Beijing, China

Qinhuangdao Hospital of Traditional Chinese Medicine

🇨🇳

Qinhuangdao, Hebei, China

Kaifeng Third People's Hospital

🇨🇳

Kaifeng, Henan, China

Shandong Public Health Clinical Center

🇨🇳

Jinan, Shandong, China

Weifang Hospital of Traditional Chinese Medicine

🇨🇳

Weifang, Shandong, China

Kunming Sanbo Brain Hospital

🇨🇳

Kunming, Yunnan, China

Second Affiliated Hospital of Tsinghua University
🇨🇳Beijing, Beijing, China
Yu Ma
Contact
© Copyright 2025. All Rights Reserved by MedPath